Author

T. Berry

Institution: Geron (United States)

Observed institutions: Geron (United States), Celgene (United States)

ORCID: 0009-0007-1862-2421

Observed ORCID: 0009-0007-1862-2421

OpenAlex ID: A5111950475

P1048: Myf3001: a Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients With Intermediate-2 or High-risk Myelofibrosis Refractory to Janus Kinase Inhibitor

2022 · J. Mascarenhas, C. N. Harrison, et al. · HemaSphere · 1

CO77 Impact of Imetelstat Treatment on PROs and Health Care Resource Utilization in Heavily Transfused Non-Del(5Q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to Erythropoiesis Stimulating Agents: IMerge Phase 3 Trial

2023 · M. Sekeres, V. Santini, et al. · Value in Health

P2.01-013 Nab-Paclitaxel/Carboplatin in Elderly Patients with NSCLC (ABOUND.70+): Analysis of Safety and Quality of Life (QoL) by Cycle

2017 · E. Kim, J. Weiss, et al. · Journal of Thoracic Oncology

nab-paclitaxel/carboplatin (nab-P/C) induction therapy in squamous (SCC) non-small cell lung cancer (NSCLC): Interim safety results from ABOUND.sqm

2017 · C. Gridelli, M. McCleod, et al. · Annals of Oncology

Works count: 4

Citation count: 1

H-index: 1

I10-index: